GILEAD’S HISTORY
OF TRANSFORMING DISEASES.

For over 30 years, we’ve strived to challenge the standard of care worldwide. We’ve developed transformative therapies for HIV, liver diseases, cardiopulmonary diseases, and oncology. We believe, with your help, we can do it again for inflammatory diseases.

Multi-colored pills

HIV

We are changing outcomes and the paradigm of care. Through our antiretroviral therapy, we’ve helped transform HIV infection from a fatal disease to a manageable condition for many.1

We’re at the forefront of pre-exposure prophylaxis (PrEP), an approach that involves the use of antiretroviral medication to reduce the chances of sexually acquiring HIV-1 infection in HIV-negative individuals at risk. And we continue to research a cure for HIV that will suppress or eliminate the virus without continuous antiretroviral therapy.

Gilead scientist in the lab

LIVER DISEASES

Gilead has helped transform the treatment of liver diseases by providing medicines that can cure chronic hepatitis C virus (HCV) infection and help manage chronic hepatitis B virus (HBV) infection.

Oncologists with his patient

ONCOLOGY

Kite, a Gilead company, is pioneering CAR T-cell therapy to help treat patients with certain hematologic cancers. This innovative approach re-engineers a patient’s white blood cells to transform their immune system into their own cancer-fighting therapy.2

OUR IMPACT, BY THE NUMBERS.

  • 130 countries

    Patients in over 130 countries reached with our treatment programs, in collaboration with international and local partners on the ground3

  • 27 marketed drugs

    27 marketed drugs and an active R&D program4

  • 11.5 million

    An estimated 11.5 million people in resource-limited countries take an HIV regimen containing a Gilead medication3

  • 2.4 million

    2.4 million bottles of Gilead HIV prevention medication to be donated to CDC annually for uninsured Americans at risk of HIV5

  • 4 million

    More than 4 million people worldwide
    have received Gilead-based curative
    HCV regimens6

References

CAR, chimeric antigen receptor; CDC, Centers for Disease Control and Prevention; R&D, research and development.

References: 1. US Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Updated December 18, 2019. Accessed January 24, 2020. 2. Data on file. Gilead Sciences, Inc.; 2017. 3. Data on file. Gilead Sciences, Inc.; 2018. 4. Gilead Life Sciences. https://www.gilead.com/science-and-medicine/medicines. Accessed September 23, 2019. 5. Data on file. Gilead Sciences, Inc.; 2019. 6. Data on file. Gilead Sciences, Inc.; 2020.

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved.
UNBP5552 07/20